 | Up a level |
Volz, Nico B; Hanna, Diana L; Stintzing, Sebastian; Zhang, Wu; Yang, Dongyun; Cao, Shu; Ning, Yan; Matsusaka, Satoshi; Sunakawa, Yu; Berger, Martin D.; Cremolini, Chiara; Loupakis, Fotios; Falcone, Alfredo; Lenz, Heinz-Josef (2020). Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients. Cancers, 12(10) MDPI AG 10.3390/cancers12102947
Berger, Martin Dave; Stintzing, Sebastian; Heinemann, Volker; Cao, Shu; Yang, Dongyun; Sunakawa, Yu; Matsusaka, Satoshi; Ning, Yan; Okazaki, Satoshi; Miyamoto, Yuji; Suenaga, Mitsukuni; Schirripa, Marta; Hanna, Diana L; Soni, Shivani; Puccini, Alberto; Zhang, Wu; Cremolini, Chiara; Falcone, Alfredo; Loupakis, Fotios and Lenz, Heinz-Josef (2018). A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab. Clinical cancer research, 24(4), pp. 784-793. American Association for Cancer Research 10.1158/1078-0432.CCR-17-1663
Okazaki, Satoshi; Stintzing, Sebastian; Sunakawa, Yu; Cao, Shu; Zhang, Wu; Yang, Dongyun; Ning, Yan; Matsusaka, Satoshi; Berger, Martin Dave; Miyamoto, Yuji; Suenaga, Mitsukuni; Schirripa, Marta; West, Jordan D; Gopez, Roel; Akihito, Tsuji; Ichikawa, Wataru; Heinemann, Volker; DePaolo, R William; Lenz, Heinz-Josef (2017). Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer. International journal of cancer, 141(6), pp. 1222-1230. Wiley-Blackwell 10.1002/ijc.30810
Berger, Martin Dave; Yamauchi, Shinichi; Cao, Shu; Hanna, Diana L; Sunakawa, Yu; Schirripa, Marta; Matsusaka, Satoshi; Yang, Dongyun; Groshen, Susan; Zhang, Wu; Ning, Yan; Okazaki, Satoshi; Miyamoto, Yuji; Suenaga, Mitsukuni; Lonardi, Sara; Cremolini, Chiara; Falcone, Alfredo; Heinemann, Volker; Loupakis, Fotios; Stintzing, Sebastian; ... (2017). Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials. European journal of cancer, 77, pp. 13-20. Elsevier 10.1016/j.ejca.2017.02.020
